PL2010219T3 - Preparaty, które stabilizują kompozycje immunogenne i hamują ich precypitację - Google Patents

Preparaty, które stabilizują kompozycje immunogenne i hamują ich precypitację

Info

Publication number
PL2010219T3
PL2010219T3 PL07760907T PL07760907T PL2010219T3 PL 2010219 T3 PL2010219 T3 PL 2010219T3 PL 07760907 T PL07760907 T PL 07760907T PL 07760907 T PL07760907 T PL 07760907T PL 2010219 T3 PL2010219 T3 PL 2010219T3
Authority
PL
Poland
Prior art keywords
stabilize
formulations
immunogenic compositions
inhibit precipitation
precipitation
Prior art date
Application number
PL07760907T
Other languages
English (en)
Inventor
Lakshmi Khandke
Ying Chen
Hanyoung Han
Robert Chancey Seid Jr
Zhaowei Jin
Jee Loon Look
Ronald Malone
Xudong Yang
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38441477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2010219(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PL2010219T3 publication Critical patent/PL2010219T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07760907T 2006-04-26 2007-04-19 Preparaty, które stabilizują kompozycje immunogenne i hamują ich precypitację PL2010219T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79526106P 2006-04-26 2006-04-26
PCT/US2007/066959 WO2007127665A2 (en) 2006-04-26 2007-04-19 Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP07760907.1A EP2010219B1 (en) 2006-04-26 2007-04-19 Formulations which stabilize and inhibit precipitation of immunogenic compositions

Publications (1)

Publication Number Publication Date
PL2010219T3 true PL2010219T3 (pl) 2016-03-31

Family

ID=38441477

Family Applications (4)

Application Number Title Priority Date Filing Date
PL07760907T PL2010219T3 (pl) 2006-04-26 2007-04-19 Preparaty, które stabilizują kompozycje immunogenne i hamują ich precypitację
PL13186454T PL2679245T3 (pl) 2006-04-26 2007-04-19 Preparaty, które stabilizują kompozycje immunogenne i hamują ich precypitację
PL13186453T PL2679244T3 (pl) 2006-04-26 2007-04-19 Preparaty, które stabilizują kompozycje immunogenne i hamują ich precypitację
PL13185292.3T PL2676679T5 (pl) 2006-04-26 2007-04-19 Nowe preparaty, które stabilizują i hamują precypitację kompozycji immunogennych

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL13186454T PL2679245T3 (pl) 2006-04-26 2007-04-19 Preparaty, które stabilizują kompozycje immunogenne i hamują ich precypitację
PL13186453T PL2679244T3 (pl) 2006-04-26 2007-04-19 Preparaty, które stabilizują kompozycje immunogenne i hamują ich precypitację
PL13185292.3T PL2676679T5 (pl) 2006-04-26 2007-04-19 Nowe preparaty, które stabilizują i hamują precypitację kompozycji immunogennych

Country Status (31)

Country Link
US (3) US7935787B2 (pl)
EP (5) EP2679245B1 (pl)
JP (7) JP5612305B2 (pl)
KR (9) KR101514847B1 (pl)
CN (4) CN105879021B (pl)
AR (2) AR060665A1 (pl)
AU (1) AU2007243019B2 (pl)
BR (2) BR122020000285B1 (pl)
CA (3) CA2650056C (pl)
CL (1) CL2007001185A1 (pl)
CR (1) CR10405A (pl)
CY (2) CY1116966T1 (pl)
DK (4) DK2679245T3 (pl)
EA (2) EA023470B1 (pl)
ES (4) ES2557504T3 (pl)
FI (2) FI2676679T4 (pl)
FR (1) FR22C1027I2 (pl)
HR (3) HRP20151203T1 (pl)
HU (5) HUE042923T2 (pl)
IL (3) IL194753A (pl)
LT (2) LT2676679T (pl)
LU (1) LUC00267I2 (pl)
MX (3) MX2008013572A (pl)
PL (4) PL2010219T3 (pl)
PT (4) PT2679245T (pl)
RU (1) RU2482878C2 (pl)
SI (4) SI2010219T1 (pl)
TR (1) TR201902402T4 (pl)
TW (1) TW200806315A (pl)
WO (1) WO2007127665A2 (pl)
ZA (1) ZA200809167B (pl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2261348A3 (en) 1998-05-01 2012-01-25 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
EP2270174A1 (en) 1999-05-19 2011-01-05 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
EP2275552B1 (en) 1999-10-29 2015-09-09 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
US7803387B2 (en) 2000-02-28 2010-09-28 Novartis Vaccines And Diagnostics Srl Heterologous expression of Neisserial proteins
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
JP2011507816A (ja) * 2007-12-21 2011-03-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム マラリア用ワクチン
BRPI0907843A2 (pt) 2008-02-21 2015-08-04 Novartis Ag Polipeptídeos de fhbp menigocócicos
HRP20201076T1 (hr) 2009-03-24 2020-10-30 Glaxosmithkline Biologicals Sa Adjuvantni vezujući protein meningokokalnog faktora h
BRPI1009829A2 (pt) * 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
CA2757620C (en) 2009-04-30 2016-04-26 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
RU2607024C2 (ru) * 2010-06-04 2017-01-10 УАЙТ ЭлЭлСи Вакцины streptococcus pneumoniae
US8802603B2 (en) 2010-06-17 2014-08-12 Becton, Dickinson And Company Medical components having coated surfaces exhibiting low friction and low reactivity
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
DK3831406T3 (da) 2010-08-23 2024-06-17 Wyeth Llc Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener
EP3056212B1 (en) 2010-09-10 2019-04-03 Wyeth LLC Non-lipidated variants of neisseria meningitidis orf2086 antigens
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
BR112013011699B1 (pt) 2010-11-11 2019-04-24 Abbvie Biotechnology Ltd FORMULAÇÕES AQUOSAS LÍQUIDAS, SERINGA PRÉ-CHEIA OU DISPOSITIVO AUTOINJETOR E USO DAS DITAS FORMULAÇÕES PARA TRATAR UM DISTÚRBIO ASSOCIADO À ATIVIDADE DE TNFa COMPROMETIDA
AR084158A1 (es) * 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
EP3780606B1 (en) 2012-06-26 2022-02-16 LG Electronics Inc. Video decoding method, video encoding method and decoder-readable storage medium storing encoded video information
JOP20200175A1 (ar) * 2012-07-03 2017-06-16 Novartis Ag حقنة
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
EP3041502A2 (en) 2013-09-08 2016-07-13 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2015059147A1 (en) * 2013-10-25 2015-04-30 Bayer Pharma Aktiengesellschaft A novel stable formulation
SG10201803187VA (en) * 2014-01-21 2018-05-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102876828B1 (ko) * 2015-06-08 2025-10-27 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 다당류-단백질 접합체의 흡착을 개선시키는 방법 및 그로부터 수득된 다가 백신 제제
EP4649956A2 (en) * 2015-07-21 2025-11-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2017098627A1 (ja) * 2015-12-10 2017-06-15 株式会社メニコン ペプチド組成物
PH12019500399B1 (en) 2016-09-02 2024-05-15 Sanofi Pasteur Inc Neisseria meningitidis vaccine
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
AU2017388891C1 (en) 2016-12-30 2025-04-17 Vaxcyte, Inc. Polypeptide-antigen conjugates with non-natural amino acids
CN106620681A (zh) * 2017-01-12 2017-05-10 南京佰泰克生物技术有限公司 一种细胞裂解液、试剂盒及在制备肿瘤全细胞抗原负载dc肿瘤疫苗中的应用
CN110234658B (zh) 2017-01-31 2024-03-12 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
EP3576759B1 (en) * 2017-01-31 2025-09-24 Merck Sharp & Dohme LLC Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
WO2018156468A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
AU2018225099B2 (en) 2017-02-24 2024-08-22 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
WO2018156467A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
BR112020004471A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
KR20200077538A (ko) * 2017-10-25 2020-06-30 머크 샤프 앤드 돔 코포레이션 아주반트 첨가된 백신
GEAP202215382A (en) 2017-12-06 2022-06-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN120661645A (zh) 2018-04-30 2025-09-19 默沙东有限责任公司 生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
EP3788143B1 (en) 2018-04-30 2023-06-28 Merck Sharp & Dohme LLC Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
US12144855B2 (en) 2018-04-30 2024-11-19 Merck Sharp & Dohme Llc Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN113272423A (zh) * 2018-09-24 2021-08-17 拜奥维萨有限责任公司 双半抗原化自体疫苗及其用途
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
AU2020355401B2 (en) 2019-09-27 2025-03-27 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
WO2022180648A1 (en) 2021-02-26 2022-09-01 Biological E Limited Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine composition
PH12023553205A1 (en) * 2021-05-28 2024-02-19 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1189340A (en) * 1967-09-13 1970-04-22 American Cyanamid Co Antigen-Adjuvant Composition
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
ES2082052T3 (es) * 1990-07-19 1996-03-16 Nardino Righi Jeringuilla de seguridad, de un solo uso.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
WO1993013302A1 (de) 1991-12-23 1993-07-08 Michael Zoche Motor mit einer vorrichtung zur entölung
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
ATE280235T1 (de) * 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP3696267B2 (ja) * 1994-02-28 2005-09-14 天野エンザイム株式会社 生理活性蛋白質の安定化方法
DE4407489A1 (de) * 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
RU2098109C1 (ru) * 1996-09-26 1997-12-10 Александр Григорьевич Чучалин Противоаллергическое, противовоспалительное средство, способ его получения, лечебное и косметическое средства с его использованием
JP4078406B2 (ja) 1997-01-22 2008-04-23 有限会社コーキ・エンジニアリング 注射器のシリンダの製造方法
JP4598201B2 (ja) * 1997-04-08 2010-12-15 メルク・シャープ・エンド・ドーム・コーポレイション 安定化ヒトパピローマウイルス製剤
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
DE69937571T2 (de) 1998-09-30 2008-09-04 The Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutiertes cholera holotoxin als hilfsmittel
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
JP2002539273A (ja) 1999-03-19 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
ES2307553T3 (es) * 1999-12-02 2008-12-01 Novartis Vaccines And Diagnostics, Inc. Composiciones y procedimientos para estabilizar moleculas biologicas tras liofilizacion.
DE10012370A1 (de) * 2000-03-14 2001-09-27 Chiron Behring Gmbh & Co Adjuvans für Vakzinen
MXPA02012010A (es) 2000-06-08 2005-04-22 Intercell Biomedizinishce Fors Oligodesoxinucleotidos inmunoestimulantes.
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
OA12302A (en) * 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
CA2416224C (en) * 2000-07-10 2015-08-25 Edwin W. Ades Multiple antigenic peptides immunogenic against streptococcus pneumoniae
GB0025414D0 (en) * 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1381381A1 (en) * 2001-03-19 2004-01-21 Gregory M. Glenn Patch for transcutaneous immunization
WO2002098369A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
MXPA03011133A (es) 2001-06-07 2004-12-06 Wyeth Corp Formas mutantes de holotoxina de colera como adyuvante.
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
EP1590459A2 (en) 2003-01-15 2005-11-02 Wyeth Holdings Corporation Methods for increasing neisseria protein expression and compositions thereof
PT2172213E (pt) * 2003-01-30 2013-06-03 Novartis Ag Vacinas injetáveis contra múltiplos serogrupos meningocócicos
SI2236154T1 (en) 2003-02-10 2018-08-31 Biogen Ma Inc. THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
AU2004233012A1 (en) 2003-04-16 2004-11-04 Wyeth Holdings Corporation Novel immunogenic compositions for the prevention and treatment of meningococcal disease
CA2529873A1 (en) * 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
UA67144A (en) * 2003-07-29 2004-06-15 Inst Exprm & Clinical Veterina Method for production of inactivated vaccine against salmonellosis and escherichiosis of animals
EP1651261B1 (en) 2003-08-06 2014-10-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Polysaccharide-protein conjugate vaccines
DE10348550A1 (de) 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
RU37462U1 (ru) * 2004-01-16 2004-04-27 Бычкова Ольга Владимировна Пробирка
MX2007005202A (es) * 2004-11-01 2007-07-09 Brigham & Womens Hospital Polisacaridos de estreptococo modificados y usos de los mismos.
DOP2006000022A (es) * 2005-01-28 2006-08-15 Wyeth Corp Formulaciones líquidas estabilizadas de polipetidos
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI511739B (zh) * 2005-04-08 2015-12-11 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
BRPI0909820A2 (pt) 2008-03-05 2015-08-11 Sanofi Pasteur Processo para estabilização de composição de vacina contra gripe, para estabilização de composição de vacina contendo adjuvante e para preparação de vacina, composições de vacina, kit de vacina e método de estocagem de uma matéria prima

Also Published As

Publication number Publication date
JP2021176910A (ja) 2021-11-11
HK1209358A1 (en) 2016-04-01
PT2679245T (pt) 2021-09-02
IL239978B (en) 2019-06-30
FIC20220022I1 (fi) 2022-06-13
SI2679244T1 (sl) 2022-05-31
SI2010219T1 (sl) 2015-12-31
PT2676679T (pt) 2019-03-01
HRP20190198T4 (hr) 2024-10-25
CN105879021B (zh) 2020-11-24
PL2679245T3 (pl) 2021-11-08
TR201902402T4 (tr) 2019-03-21
SI2679245T1 (sl) 2021-11-30
CN101500612A (zh) 2009-08-05
CN103768615A (zh) 2014-05-07
RU2008141680A (ru) 2010-06-10
EA200870480A1 (ru) 2009-04-28
HRP20190198T1 (hr) 2019-04-05
CN103768615B (zh) 2016-06-01
CY1116966T1 (el) 2017-04-05
TW200806315A (en) 2008-02-01
EP2679245A2 (en) 2014-01-01
KR20210111326A (ko) 2021-09-10
KR20140132779A (ko) 2014-11-18
EA017436B1 (ru) 2012-12-28
DK2676679T3 (en) 2019-03-04
CR10405A (es) 2009-02-26
RU2482878C2 (ru) 2013-05-27
SI2676679T1 (sl) 2019-03-29
DK2679244T3 (da) 2022-04-11
KR20170122857A (ko) 2017-11-06
JP2014221806A (ja) 2014-11-27
ES2712956T5 (en) 2025-02-10
CA2650056C (en) 2013-07-16
FR22C1027I1 (fr) 2022-09-09
WO2007127665A2 (en) 2007-11-08
AR110731A2 (es) 2019-04-24
IL239788A0 (en) 2015-08-31
IL239978A0 (en) 2015-08-31
HUE058394T2 (hu) 2022-08-28
EA201200929A1 (ru) 2013-05-30
KR20200032268A (ko) 2020-03-25
JP5612305B2 (ja) 2014-10-22
EP2676679A3 (en) 2014-01-01
CA2650056A1 (en) 2007-11-08
FI2676679T4 (fi) 2024-10-31
CN104857524A (zh) 2015-08-26
US20110172393A1 (en) 2011-07-14
KR101514913B1 (ko) 2015-04-23
DK2010219T3 (en) 2016-01-11
EP2679245A3 (en) 2014-01-15
PT2010219E (pt) 2016-01-29
HRP20211417T1 (hr) 2021-12-10
EP3517129A1 (en) 2019-07-31
ES2557504T3 (es) 2016-01-26
WO2007127665A3 (en) 2008-11-13
EP2010219B1 (en) 2015-10-28
MX359741B (es) 2018-10-09
US8562999B2 (en) 2013-10-22
US20070253984A1 (en) 2007-11-01
BRPI0710918A2 (pt) 2012-03-06
KR20140004258A (ko) 2014-01-10
HUS2200028I1 (hu) 2022-07-28
ZA200809167B (en) 2009-06-24
HK1196546A1 (zh) 2014-12-19
AU2007243019B2 (en) 2012-06-21
JP2018123145A (ja) 2018-08-09
HUE028137T2 (hu) 2016-11-28
BRPI0710918B1 (pt) 2021-02-02
CA2803111A1 (en) 2007-11-08
PL2676679T3 (pl) 2019-06-28
DK2679245T3 (da) 2021-09-06
KR102093269B1 (ko) 2020-04-23
ES2910432T3 (es) 2022-05-12
PL2679244T3 (pl) 2022-06-20
KR20090017537A (ko) 2009-02-18
LUC00267I2 (pl) 2025-04-25
EP2679244A3 (en) 2014-01-15
US20130034580A1 (en) 2013-02-07
EP2679244A2 (en) 2014-01-01
CA2873346C (en) 2017-09-05
MX2008013572A (es) 2009-03-06
IL194753A (en) 2015-08-31
FR22C1027I2 (fr) 2024-10-11
US7935787B2 (en) 2011-05-03
JP2016222701A (ja) 2016-12-28
KR20220061256A (ko) 2022-05-12
JP2014055169A (ja) 2014-03-27
KR101514913B9 (en) 2022-06-24
BR122020000285B1 (pt) 2023-05-09
AU2007243019A1 (en) 2007-11-08
EA023470B1 (ru) 2016-06-30
KR101514847B1 (ko) 2015-04-24
KR20160049063A (ko) 2016-05-04
LT2676679T (lt) 2019-03-12
EP2676679B2 (en) 2024-08-28
SI2676679T2 (sl) 2025-05-30
CA2873346A1 (en) 2007-11-08
HUE055682T2 (hu) 2021-12-28
JP6321094B2 (ja) 2018-05-09
EP2676679B1 (en) 2019-01-02
ES2712956T3 (es) 2019-05-16
PL2676679T5 (pl) 2024-11-12
LTC2676679I2 (pl) 2025-04-10
CL2007001185A1 (es) 2008-01-18
EP2679244B1 (en) 2022-03-23
PT2679244T (pt) 2022-04-19
EP2676679A2 (en) 2013-12-25
CN104857524B (zh) 2018-08-28
ES2885762T3 (es) 2021-12-15
MX2018012171A (es) 2021-12-08
IL194753A0 (en) 2009-08-03
LTPA2022509I1 (pl) 2022-06-27
JP2019194240A (ja) 2019-11-07
CN101500612B (zh) 2013-12-25
CA2803111C (en) 2015-06-16
CN105879021A (zh) 2016-08-24
KR20180130004A (ko) 2018-12-05
JP2009535353A (ja) 2009-10-01
DK2676679T4 (da) 2024-09-16
JP6192115B2 (ja) 2017-09-06
EP2010219A2 (en) 2009-01-07
HUE042923T2 (hu) 2019-07-29
EP2679245B1 (en) 2021-07-28
HRP20151203T1 (hr) 2015-12-04
HK1223569A1 (zh) 2017-08-04
AR060665A1 (es) 2008-07-02
BRPI0710918B8 (pt) 2021-05-25
CY1121251T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
HUS2200028I1 (hu) Immunogén készítmények stabilizálására és kicsapódásuk gátlására szolgáló kiszerelések
IL190885A0 (en) Immunogenic compositions and methods of use
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
ZA201203709B (en) Immunogenic compositions and methods
EP1988918A4 (en) ADJUVANZ AND VACCINE COMPOSITIONS
ZA200900347B (en) Preparation of pharmaceutical compositions
PT2101766T (pt) Composições e métodos de utilização de (r)-pramipexole
IL198513A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
IL197909A0 (en) Reduction of astringency in polyphenol compositions
PL2101766T3 (pl) Kompozycje i sposoby stosowania (R)-pramipeksolu
ZA200810162B (en) Phenylphrine pulsed release formulations and pharmaceutical compositions
ZA200900416B (en) Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
ZA200908300B (en) Natural honey-containing compositions and method of preparation
EP2076281A4 (en) STABILIZING ALKYLGLYCOSIDIC COMPOSITIONS AND METHODS THEREOF
GB0401964D0 (en) Compositions for use as biocides and biostatics and uses of said compositions
IL192614A0 (en) Antiseptic compositions and methods of using same
ZA200806668B (en) Antiseptic compositions and methods of using same
AU2006906669A0 (en) Methods and Preparation and Uses of Xanthorrhoeaceae Compositions